查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088897

禽流感治療藥物市場：按產品類型、給藥途徑、最終用戶和應用分類的全球市場預測，2026-2032年

Bird Flu Treatment Market by Product Type, Administration Route, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，禽流感治療市場規模將達到 197.5 億美元，複合年成長率為 6.72%。

主要市場統計數據
基準年 2025 125.2億美元
預計年份：2026年 133.1億美元
預測年份 2032 197.5億美元
複合年成長率 (%) 6.72%

禽流感治療市場執行摘要

禽流感治療正從一項暫時的公共衛生問題轉變為各國政府、製藥企業、醫療衛生系統和動物健康相關人員的策略重點。雖然包括H5N1、H7N9和其他通用亞型在內的禽流感A病毒感染人類的病例仍然罕見，但臨床風險極高。根據世界衛生組織的監測，自2003年以來，已報告超過900例H5N1人感染疾病病例，且通報病例的死亡率處於歷史高點。

禽流感治療的革命性變革

高致病性禽流感的地理擴散、哺乳動物感染病例的不斷增加以及對人畜共患感染疾病日益成長的擔憂，正在改變通用感的治療模式。自2021年以來，H5N1病毒2.3.4.4b分支已在多個地區的野生和家養鳥類中引發大規模疫情，凸顯了快速檢測、早期治療方案以及採取更有效的抗病毒措施的迫切需求。

人工智慧的累積影響

人工智慧（AI）在應對禽流感方面正變得日益重要，因為治療決策取決於速度、亞型識別和風險評估。人工智慧驅動的基因組監測有助於識別與哺乳動物適應性、抗病毒藥物抗藥性或抗原漂移相關的突變，從而使公共衛生機構和製藥公司能夠更有效地確定潛在的應對策略的優先順序。

按地區分類的主要發現

亞太地區在禽流感防治方面仍然至關重要，因為該地區反覆爆發與禽流感亞型（包括H5N1和H7N9）相關的人類感染疫情，且該地區家禽生產高度集中，與活禽市場接觸頻繁，並存在跨多個國家的大規模區域間貿易。在北美，由於在野生鳥類、家禽、哺乳動物和美國乳牛中廣泛檢測到H5N1病毒，警覺性已顯著提高，並日益重視職業監測、抗病毒藥物和診斷的獲取以及對接觸過病毒的工人進行風險溝通。

主要群體分析

由於東南亞國協過程在禽流感治療需求方面發揮著核心作用。海灣合作理事會（GCC）國家也出於對先進診斷技術和協調一致的緊急應變系統的需求，將衛生安全、進口管制、醫院準備和大規模公共部門採購列為優先事項。

主要國家的概況

美國優先進行H5N1禽流感監測、抗病毒藥物指南、職業風險監測以及公共衛生、農業和酪農企業之間的協調工作；加拿大則專注於野生動物、家禽和公共衛生之間的協調，並依賴全國性的監測系統。墨西哥和巴西由於家禽生產規模龐大、參與區域貿易以及保護食品供應鏈的必要性，處於關鍵地位。英國、德國、法國、義大利和西班牙則持續透過歐洲公共衛生和動物衛生框架加強監測、檢測能力、抗病毒藥物儲備和緊急應變能力。

為行業領導者提供的實用建議

產業領導者應優先考慮以實證醫學為基礎的抗病毒藥物組合、可擴展的生產能力以及奧司他韋和其他具有重要臨床意義的流感治療藥物的穩健供應鏈。各公司應根據美國疾病管制與預防中心 (CDC)、世界衛生組織 (WHO) 和國家臨床指南制定產品策略，強調對疑似或確診的人禽流感病例進行早期治療，尤其要關注有高風險暴露史的患者、重症患者或與感染動物有職業接觸的人員。

調查方法

本執行摘要基於二手研究，參考了經檢驗的公共衛生、監管和科學資訊來源，包括世界衛生組織（WHO）、美國疾病管制與預防中心（CDC）、世界動物衛生組織（WOAH）、聯合國糧農組織（FAO）、各國衛生機構、同儕審查文獻和官方監測更新。分析重點在於公開可用的證據，包括臨床認可的治療方法、已記錄的流行病學模式、區域準備指標、抗病毒抗藥性考量、診斷能力和禽流感流行病學。

結論

由於多種因素的共同作用，禽流感治療的需求正在增加：通用感染疾病的風險、監測系統的擴展、抗病毒藥物儲備的需求以及對更快臨床反應的需求。雖然人類病例仍然罕見，但已報告感染的嚴重程度以及高致病性禽流感的全球傳播，都證明了繼續投資於治療、診斷、儲備和「同一健康」基礎設施的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 禽流感治療市場：依產品類型分類

  • 抗病毒藥物
    • 基於金剛烷的化學品
    • 聯合治療
    • 神經氨酸酶抑制劑
    • 聚合酵素抑制劑
  • 支持性護理
    • 氧氣療法
    • 水療法
    • 症狀管理
    • 遠端醫療監測
  • 疫苗
    • 去活化疫苗
    • 減毒活疫苗
    • 藥效疫苗
    • 重組疫苗

第8章 禽流感治療藥物市場：依給藥途徑分類

  • 吸入
    • 乾粉吸入器
    • 定量噴霧吸入器
    • 噴霧器
  • 注射藥物
    • 肌肉內部
    • 奈米顆粒遞送
    • 皮下
  • 靜脈
    • 中央靜脈導管
    • 周邊管路
    • 智慧型輸液幫浦
  • 口服
    • 膠囊
    • 舌下給藥
    • 懸浮液
    • 藥片

第9章：禽流感治療市場：依最終用戶分類

  • 診所
    • 社區健康中心
    • 門診部
    • 專科診所
  • 醫院
    • 私立醫院
    • 公立醫院
    • 專業治療中心
  • 研究所
    • 醫院檢查室
    • 獨立檢測實驗室
    • 即時檢測
  • 藥局
    • 郵購藥房
    • 網路藥房
    • 零售藥房

第10章：禽流感治療市場：依應用分類

  • 動物健康
    • 家畜
    • 家禽
    • 野生鳥類
  • 人類健康
    • 成年患者
    • 老年患者
    • 兒童患者

第11章 禽流感治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 禽流感治療藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 禽流感治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Alltech, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Cipla Limited
  • CSL Limited
  • F. Hoffmann-La Roche Ltd.
  • FATRO SpA
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hester Biosciences Limited
  • Johnson & Johnson Services, Inc.
  • Macleods Pharmaceuticals Ltd
  • Merck KGaA
  • Moderna, Inc.
  • Novartis AG
  • PetSmart LLC
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • Tianjin Ringpu Biotechnology Co. Ltd.
  • Yebio Bioengineering Co. Ltd.
  • Zoetis Inc.
Product Code: MRR-CA17E905EAFA

The Bird Flu Treatment Market is projected to grow by USD 19.75 billion at a CAGR of 6.72% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 12.52 billion
Estimated Year [2026] USD 13.31 billion
Forecast Year [2032] USD 19.75 billion
CAGR (%) 6.72%

Bird Flu Treatment Market Executive Summary

Bird flu treatment is moving from an episodic public health concern to a strategic priority for governments, pharmaceutical manufacturers, healthcare systems, and animal health stakeholders. Human infections with avian influenza A viruses such as H5N1, H7N9, and other zoonotic subtypes remain uncommon, but the clinical stakes are high: WHO surveillance has documented more than 900 human H5N1 cases since 2003, with historically high case fatality among reported infections.

Current treatment strategies emphasize rapid antiviral initiation, supportive clinical care, infection prevention, and coordinated One Health surveillance across poultry, wild birds, mammals, and humans. The market demand is being shaped by neuraminidase inhibitors such as oseltamivir, zanamivir, and peramivir, investigational therapeutics, diagnostic testing, antiviral stockpiling, and pandemic preparedness programs.

Transformative Shifts in Bird Flu Treatment

The bird flu treatment landscape is being reshaped by wider geographic spread of highly pathogenic avian influenza, growing mammalian detections, and heightened concern over zoonotic spillover. Since 2021, H5N1 clade 2.3.4.4b has driven extensive outbreaks in wild birds and poultry across multiple regions, increasing demand for faster detection, early treatment protocols, and stronger antiviral readiness.

Treatment pathways are also shifting from hospital-centered response to integrated preparedness. Governments and health systems are strengthening antiviral reserves, updating clinical guidance, expanding sequencing capacity, and connecting veterinary surveillance with human health alert systems. This transition is creating new opportunities for antiviral manufacturers, diagnostic developers, cold-chain providers, and clinical research organizations.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly important in avian influenza response because treatment decisions depend on speed, subtype identification, and risk assessment. AI-enabled genomic surveillance can help flag mutations associated with mammalian adaptation, antiviral resistance, or antigenic drift, allowing public health agencies and manufacturers to prioritize candidate countermeasures more efficiently.

In clinical and commercial settings, AI can support outbreak forecasting, hospital triage workflows, drug repurposing, pharmacovigilance, and supply planning for antivirals and diagnostics. The cumulative impact is strongest when AI outputs are validated against laboratory-confirmed data, transparent epidemiological models, and regulatory-grade evidence rather than used as stand-alone decision tools.

Key Regional Insights

Asia-Pacific remains a critical region for bird flu treatment because it has experienced repeated human infections linked to avian influenza subtypes, including H5N1 and H7N9, alongside dense poultry production, live bird market exposure, and high-volume regional trade in several countries. North America has intensified preparedness following widespread H5N1 detections in wild birds, poultry, mammals, and U.S. dairy cattle, increasing emphasis on occupational monitoring, antivirals, diagnostic access, and risk communication for exposed workers.

Europe continues to invest in surveillance and cross-border response through public health and animal health coordination, while Latin America has expanded attention to poultry protection, wildlife monitoring, and treatment readiness after regional H5N1 incursions in birds and marine mammals. The Middle East's risk profile is linked to migratory bird routes, poultry imports, live animal movement, and healthcare preparedness, whereas Africa faces added challenges from limited laboratory capacity, uneven antiviral availability, underreported outbreaks, and the need for stronger One Health infrastructure.

Key Group Insights

ASEAN markets are central to bird flu treatment demand because poultry density, cross-border trade, live bird market interfaces, and historical avian influenza outbreaks require integrated surveillance and rapid access to antivirals. The GCC is prioritizing health security, import controls, hospital preparedness, and high-capacity public-sector procurement, supported by interest in advanced diagnostics and coordinated emergency response systems.

The European Union benefits from harmonized animal disease reporting, centralized regulatory pathways, coordinated preparedness planning, and established laboratory networks, making it a major reference point for avian influenza response standards. BRICS countries represent a large treatment opportunity due to population scale, poultry production intensity, vaccine and pharmaceutical manufacturing capacity, and varied exposure to poultry and wildlife reservoirs. G7 and NATO members influence antiviral stockpiling, research funding, biosurveillance interoperability, supply chain resilience, and emergency response coordination across allied healthcare, agriculture, and defense systems.

Key Country Insights

The United States is prioritizing H5N1 surveillance, antiviral guidance, occupational risk monitoring, and coordination between public health, agriculture, and dairy operations, while Canada is focused on wildlife, poultry, and public health coordination supported by national surveillance systems. Mexico and Brazil are important due to poultry production scale, regional trade exposure, and the need to protect food supply chains. The United Kingdom, Germany, France, Italy, and Spain continue to strengthen surveillance, laboratory capacity, antiviral readiness, and preparedness through European public health and animal health frameworks.

Russia's geographic scale, poultry sector, and migratory bird pathways make monitoring strategically important. China and India combine large poultry sectors, dense population interfaces, prior avian influenza experience, and substantial domestic pharmaceutical capacity, making them central to treatment access and outbreak control. Japan, Australia, and South Korea maintain advanced diagnostics, strict biosecurity, national stockpiling policies, and strong public health systems that support rapid clinical response, subtype confirmation, and antiviral deployment.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-based antiviral portfolios, scalable manufacturing, and resilient supply chains for oseltamivir and other clinically relevant influenza therapeutics. Companies should align product strategy with CDC, WHO, and national clinical guidance emphasizing early treatment for suspected or confirmed human avian influenza, particularly among patients with high-risk exposure, severe disease, or occupational contact with infected animals.

Executives should invest in companion diagnostics, resistance monitoring, genomic surveillance partnerships, and real-world evidence generation. Commercial teams can strengthen market positioning by supporting government stockpiles, hospital protocols, occupational health programs, pharmacist education, cold-chain readiness, and One Health collaborations that connect poultry producers, veterinarians, laboratories, and public health agencies.

Research Methodology

This executive summary is based on secondary research from verified public health, regulatory, and scientific sources, including WHO, CDC, WOAH, FAO, national health agencies, peer-reviewed literature, and official surveillance updates. The analysis emphasizes clinically accepted treatment approaches, documented outbreak patterns, regional preparedness indicators, antiviral resistance considerations, diagnostic capacity, and publicly available evidence on avian influenza epidemiology.

The methodology applies a structured market intelligence framework that triangulates disease surveillance, treatment guidance, policy developments, procurement behavior, technology adoption, and One Health response priorities. Insights are synthesized to support strategic planning across pharmaceuticals, diagnostics, healthcare delivery, animal health, and government preparedness without relying on speculative or unverified claims.

Conclusion

Bird flu treatment demand is being driven by the convergence of zoonotic risk, expanding surveillance, antiviral preparedness, and the need for faster clinical response. Although human cases remain rare, the severity of reported infections and the global spread of highly pathogenic avian influenza justify sustained investment in therapeutics, diagnostics, stockpiling, and One Health infrastructure.

The strongest market opportunities will favor organizations that combine regulatory readiness, scientific credibility, scalable production, validated diagnostics, and public-sector collaboration. As AI, genomic sequencing, and integrated surveillance mature, the bird flu treatment landscape is expected to become more proactive, data-driven, and preparedness-oriented.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Bird Flu Treatment Market, by Product Type

  • 7.1. Antiviral Drug
    • 7.1.1. Adamantanes
    • 7.1.2. Combination Therapy
    • 7.1.3. Neuraminidase Inhibitors
    • 7.1.4. Polymerase Inhibitors
  • 7.2. Supportive Care
    • 7.2.1. Oxygen Therapy
    • 7.2.2. Rehydration Therapy
    • 7.2.3. Symptom Management
    • 7.2.4. Telehealth Monitoring
  • 7.3. Vaccine
    • 7.3.1. Inactivated Vaccine
    • 7.3.2. Live Attenuated Vaccine
    • 7.3.3. Mrna Vaccine
    • 7.3.4. Recombinant Vaccine

8. Bird Flu Treatment Market, by Administration Route

  • 8.1. Inhalation
    • 8.1.1. Dry Powder Inhaler
    • 8.1.2. Metered Dose Inhaler
    • 8.1.3. Nebulizer
  • 8.2. Injectable
    • 8.2.1. Intramuscular
    • 8.2.2. Nanoparticle Delivery
    • 8.2.3. Subcutaneous
  • 8.3. Intravenous
    • 8.3.1. Central Line
    • 8.3.2. Peripheral Line
    • 8.3.3. Smart Infusion Pumps
  • 8.4. Oral
    • 8.4.1. Capsule
    • 8.4.2. Sublingual
    • 8.4.3. Suspension
    • 8.4.4. Tablet

9. Bird Flu Treatment Market, by End User

  • 9.1. Clinics
    • 9.1.1. Community Health Centers
    • 9.1.2. Outpatient Clinics
    • 9.1.3. Specialty Clinics
  • 9.2. Hospitals
    • 9.2.1. Private Hospitals
    • 9.2.2. Public Hospitals
    • 9.2.3. Specialized Care Centers
  • 9.3. Laboratories
    • 9.3.1. Hospital Labs
    • 9.3.2. Independent Labs
    • 9.3.3. Point Of Care Testing
  • 9.4. Pharmacies
    • 9.4.1. Mail Order Pharmacies
    • 9.4.2. Online Pharmacies
    • 9.4.3. Retail Pharmacies

10. Bird Flu Treatment Market, by Application

  • 10.1. Animal Health
    • 10.1.1. Livestock
    • 10.1.2. Poultry
    • 10.1.3. Wild Birds
  • 10.2. Human Health
    • 10.2.1. Adult Patients
    • 10.2.2. Geriatric Patients
    • 10.2.3. Pediatric Patients

11. Bird Flu Treatment Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Bird Flu Treatment Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Bird Flu Treatment Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Alltech, Inc.
  • 15.2. BioCryst Pharmaceuticals, Inc.
  • 15.3. Boehringer Ingelheim International GmbH
  • 15.4. Ceva Sante Animale
  • 15.5. Cipla Limited
  • 15.6. CSL Limited
  • 15.7. F. Hoffmann-La Roche Ltd.
  • 15.8. FATRO S.p.A.
  • 15.9. Gilead Sciences, Inc.
  • 15.10. GlaxoSmithKline PLC
  • 15.11. Hester Biosciences Limited
  • 15.12. Johnson & Johnson Services, Inc.
  • 15.13. Macleods Pharmaceuticals Ltd
  • 15.14. Merck KGaA
  • 15.15. Moderna, Inc.
  • 15.16. Novartis AG
  • 15.17. PetSmart LLC
  • 15.18. Pfizer Inc.
  • 15.19. Sanofi S.A.
  • 15.20. Serum Institute of India Pvt. Ltd.
  • 15.21. Sinovac Biotech Ltd.
  • 15.22. Takeda Pharmaceutical Company Limited
  • 15.23. Tianjin Ringpu Biotechnology Co. Ltd.
  • 15.24. Yebio Bioengineering Co. Ltd.
  • 15.25. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIRD FLU TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL BIRD FLU TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL BIRD FLU TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL BIRD FLU TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL BIRD FLU TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIRD FLU TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL BIRD FLU TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL BIRD FLU TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL BIRD FLU TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIRD FLU TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL BIRD FLU TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIRD FLU TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL BIRD FLU TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BIRD FLU TREATMENT MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL BIRD FLU TREATMENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BIRD FLU TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL BIRD FLU TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL BIRD FLU TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL BIRD FLU TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL BIRD FLU TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL BIRD FLU TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIRD FLU TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIRD FLU TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIVIRAL DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ADAMANTANES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ADAMANTANES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ADAMANTANES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEURAMINIDASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEURAMINIDASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEURAMINIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POLYMERASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POLYMERASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POLYMERASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OXYGEN THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OXYGEN THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OXYGEN THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL REHYDRATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL REHYDRATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL REHYDRATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SYMPTOM MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SYMPTOM MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SYMPTOM MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TELEHEALTH MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TELEHEALTH MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TELEHEALTH MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INACTIVATED VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INACTIVATED VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INACTIVATED VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIVE ATTENUATED VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LIVE ATTENUATED VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LIVE ATTENUATED VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MRNA VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MRNA VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MRNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RECOMBINANT VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RECOMBINANT VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RECOMBINANT VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIRD FLU TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INHALATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DRY POWDER INHALER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRY POWDER INHALER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DRY POWDER INHALER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL METERED DOSE INHALER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL METERED DOSE INHALER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL METERED DOSE INHALER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEBULIZER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEBULIZER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEBULIZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NANOPARTICLE DELIVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NANOPARTICLE DELIVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NANOPARTICLE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CENTRAL LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CENTRAL LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CENTRAL LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PERIPHERAL LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PERIPHERAL LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PERIPHERAL LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SMART INFUSION PUMPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SMART INFUSION PUMPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SMART INFUSION PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SUBLINGUAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SUBLINGUAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SUBLINGUAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SUSPENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SUSPENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SUSPENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL TABLET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL TABLET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIRD FLU TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL COMMUNITY HEALTH CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL COMMUNITY HEALTH CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL COMMUNITY HEALTH CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL OUTPATIENT CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL OUTPATIENT CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL OUTPATIENT CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL SPECIALIZED CARE CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL SPECIALIZED CARE CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL SPECIALIZED CARE CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL HOSPITAL LABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL HOSPITAL LABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL HOSPITAL LABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL INDEPENDENT LABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL INDEPENDENT LABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL INDEPENDENT LABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL MAIL ORDER PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL MAIL ORDER PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL MAIL ORDER PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIRD FLU TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ANIMAL HEALTH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANIMAL HEALTH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ANIMAL HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL LIVESTOCK MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL LIVESTOCK MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL LIVESTOCK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL POULTRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL POULTRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL POULTRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL WILD BIRDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL WILD BIRDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL WILD BIRDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL HUMAN HEALTH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL HUMAN HEALTH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL HUMAN HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL ADULT PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ADULT PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ADULT PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL GERIATRIC PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL GERIATRIC PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL GERIATRIC PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL BIRD FLU TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC BIRD FLU TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC BIRD FLU TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC BIRD FLU TREATMENT MARKET SIZE, BY ANTIVIRAL DRUG, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC BIRD FLU TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC BIRD FLU TREATMENT MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC BIRD FLU TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC BIRD FLU TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC BIRD FLU TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC BIRD FLU TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC BIRD FLU TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC BIRD FLU TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC BIRD FLU TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC BIRD FLU TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC BIRD FLU TREATMENT MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC BIRD FLU TREATMENT MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC BIRD FLU TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC BIRD FLU TREATMENT MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC BIRD FLU TREATMENT MARKET SIZE, BY HUMAN HEALTH, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA BIRD FLU TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA BIRD FLU TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA BIRD FLU TREATMENT MARKET SIZE, BY ANTIVIRAL DRUG, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA BIRD FLU TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA BIRD FLU TREATMENT MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA BIRD FLU TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA BIRD FLU TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA BIRD FLU TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA BIRD FLU TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA BIRD FLU TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA BIRD FLU TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA BIRD FLU TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA BIRD FLU TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA BIRD FLU TREATMENT MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA BIRD FLU TREATMENT MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA BIRD FLU TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA BIRD FLU TREATMENT MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA BIRD FLU TREATMENT MARKET SIZE, BY HUMAN HEALTH, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA BIRD FLU TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA BIRD FLU TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA BIRD FLU TREATMENT MARKET SIZE, BY ANTIVIRAL DRUG, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA BIRD FLU TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA BIRD FLU TREATMENT MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA BIRD FLU TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA BIRD FLU TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA BIRD FLU TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA BIRD FLU TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA BIRD FLU TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA BIRD FLU TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA BIRD FLU TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA BIRD FLU TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA BIRD FLU TREATMENT MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA BIRD FLU TREATMENT MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA BIRD FLU TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA BIRD FLU TREATMENT MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA BIRD FLU TREATMENT MARKET SIZE, BY HUMAN HEALTH, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE BIRD FLU TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE BIRD FLU TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE BIRD FLU TREATMENT MARKET SIZE, BY ANTIVIRAL DRUG, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE BIRD FLU TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE BIRD FLU TREATMENT MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE BIRD FLU TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE BIRD FLU TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE BIRD FLU TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE BIRD FLU TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE BIRD FLU TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE BIRD FLU TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE BIRD FLU TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE BIRD FLU TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE BIRD FLU TREATMENT MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE BIRD FLU TREATMENT MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE BIRD FLU TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE BIRD FLU TREATMENT MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE BIRD FLU TREATMENT MARKET SIZE, BY HUMAN HEALTH, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST BIRD FLU TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST BIRD FLU TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST BIRD FLU TREATMENT MARKET SIZE, BY ANTIVIRAL DRUG, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST BIRD FLU TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST BIRD FLU TREATMENT MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST BIRD FLU TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST BIRD FLU TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST BIRD FLU TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST BIRD FLU TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST BIRD FLU TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST BIRD FLU TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST BIRD FLU TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST BIRD FLU TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST BIRD FLU TREATMENT MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST BIRD FLU TREATMENT MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST BIRD FLU TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST BIRD FLU TREATMENT MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST BIRD FLU TREATMENT MARKET SIZE, BY HUMAN HEALTH, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA BIRD FLU TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA BIRD FLU TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA BIRD FLU TREATMENT MARKET SIZE, BY ANTIVIRAL DRUG, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA BIRD FLU TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA BIRD FLU TREATMENT MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA BIRD FLU TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA BIRD FLU TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA BIRD FLU TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA BIRD FLU TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA BIRD FLU TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA BIRD FLU TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA BIRD FLU TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA BIRD FLU TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA BIRD FLU TREATMENT MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA BIRD FLU TREATMENT MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA BIRD FLU TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 281. AFRICA BIRD FLU TREATMENT MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA BIRD FLU TREATMENT MARKET SIZE, BY HUMAN HEALTH, 2018-2032 (USD MILLION)
  • TABLE 283. GLOBAL BIRD FLU TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN BIRD FLU TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN BIRD FLU TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. ASEAN BIRD FLU TREATMENT MARKET SIZE, BY ANTIVIRAL DRUG, 2018-2032 (USD MILLION)
  • TABLE 287. ASEAN BIRD FLU TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 288. ASEAN BIRD FLU TREATMENT MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 289. ASEAN BIRD FLU TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 290. ASEAN BIRD FLU TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 291. ASEAN BIRD FLU TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 292. ASEAN BIRD FLU TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 293. ASEAN BIRD FLU TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 294. ASEAN BIRD FLU TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. ASEAN BIRD FLU TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 296. ASEAN BIRD FLU TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 297. ASEAN BIRD FLU TREATMENT MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 298. ASEAN BIRD FLU TREATMENT MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 299. ASEAN BIRD FLU TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 300. ASEAN BIRD FLU TREATMENT MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 301. ASEAN BIRD FLU TREATMENT MARKET SIZE, BY HUMAN HEALTH, 2018-2032 (USD MILLION)
  • TABLE 302. GCC BIRD FLU TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 303. GCC BIRD FLU TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. GCC BIRD FLU TREATMENT MARKET SIZE, BY ANTIVIRAL DRUG, 2018-2032 (USD MILLION)
  • TABLE 305. GCC BIRD FLU TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 306. GCC BIRD FLU TREATMENT MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 307. GCC BIRD FLU TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 308. GCC BIRD FLU TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 309. GCC BIRD FLU TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 310. GCC BIRD FLU TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 311. GCC BIRD FLU TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 312. GCC BIRD FLU TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. GCC BIRD FLU TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 314. GCC BIRD FLU TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 315. GCC BIRD FLU TREATMENT MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 316. GCC BIRD FLU TREATMENT MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 317. GCC BIRD FLU TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 318. GCC BIRD FLU TREATMENT MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 319. GCC BIRD FLU TREATMENT MARKET SIZE, BY HUMAN HEALTH, 2018-2032 (USD MILLION)
  • TABLE 320. EUROPEAN UNION BIRD FLU TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 321. EUROPEAN UNION BIRD FLU TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. EUROPEAN UNION BIRD FLU TREATMENT MARKET SIZE, BY ANTIVIRAL DRUG, 2018-2032 (USD MILLION)
  • TABLE 323. EUROPEAN UNION BIRD FLU TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 324. EUROPEAN UNION BIRD FLU TREATMENT MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 325. EUROPEAN UNION BIRD FLU TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 326. EUROPEAN UNION BIRD FLU TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION BIRD FLU TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 328. EUROPEAN UNION BIRD FLU TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION BIRD FLU TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 330. EUROPEAN UNION BIRD FLU TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 331. EUROPEAN UNION BIRD FLU TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 332. EUROPEAN UNION BIRD FLU TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION BIRD FLU TREATMENT MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 334. EUROPEAN UNION BIRD FLU TREATMENT MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION BIRD FLU TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 336. EUROPEAN UNION BIRD FLU TREATMENT MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 337. EUROPEAN UNION BIRD FLU TREATMENT MARKET SIZE, BY HUMAN HEALTH, 2018-2032 (USD MILLION)
  • TABLE 338. BRICS BIRD FLU TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 339. BRICS BIRD FLU TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 340. BRICS BIRD FLU TREATMENT MARKET SIZE, BY ANTIVIRAL DRUG, 2018-2032 (USD MILLION)
  • TABLE 341. BRICS BIRD FLU TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 342. BRICS BIRD FLU TREATMENT MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 343. BRICS BIRD FLU TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 344. BRICS BIRD FLU TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 345. BRICS BIRD FLU TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 346. BRICS BIRD FLU TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 347. BRICS BIRD FLU TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 348. BRICS BIRD FLU TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 349. BRICS BIRD FLU TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 350. BRICS BIRD FLU TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 351. BRICS BIRD FLU TREATMENT MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 352. BRICS BIRD FLU TREATMENT MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 353. BRICS BIRD FLU TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 354. BRICS BIRD FLU TREATMENT MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 355. BRICS BIRD FLU TREATMENT MARKET SIZE, BY HUMAN HEALTH, 2018-2032 (USD MILLION)
  • TABLE 356. G7 BIRD FLU TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 357. G7 BIRD FLU TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 358. G7 BIRD FLU TREATMENT MARKET SIZE, BY ANTIVIRAL DRUG, 2018-2032 (USD MILLION)
  • TABLE 359. G7 BIRD FLU TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 360. G7 BIRD FLU TREATMENT MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 361. G7 BIRD FLU TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 362. G7 BIRD FLU TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 363. G7 BIRD FLU TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 364. G7 BIRD FLU TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 365. G7 BIRD FLU TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 366. G7 BIRD FLU TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 367. G7 BIRD FLU TREATMENT MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 368. G7 BIRD FLU TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 369. G7 BIRD FLU TREATMENT MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 370. G7 BIRD FLU TREATMENT MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 371. G7 BIRD FLU TREATMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 372. G7 BIRD FLU TREATMENT MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 373. G7 BIRD FLU TREATMENT MARKET SIZE, BY HUMAN HEALTH, 2018-2032 (USD MILLION)
  • TABLE 374. NATO BIRD FLU TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 375. NATO BIRD FLU TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 376. NATO BIRD FLU TREATMENT MARKET SIZE, BY ANTIVIRAL DRUG, 2018-2032 (USD MILLION)
  • TABLE 377. NATO BIRD FLU TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 378. NATO BIRD FLU TREATMENT MARKET SIZE, BY VACCINE, 2018-2032 (USD MILLION)
  • TABLE 379. NATO BIRD FLU TREATMENT MARKET SIZE, BY AD